A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.

Author(s): Miller TP,  Getz KD,  Kavcic M,  Li Y,  Huang YS,  Sung L,  Alonzo TA,  Gerbing R,  Daves M,  Horton TM,  Pulsipher MA,  Pollard J,  Bagatell R,  Seif AE,  Fisher BT,  Gamis AS,  Aplenc R

Journal: Leuk Lymphoma

Date: 2016 Jul

Major Program(s) or Research Group(s): NCORP

PubMed ID: 26727639

PMC ID: PMC4899280

Abstract: While most children receive acute myeloid leukemia (AML) chemotherapy as inpatients, there is variability in timing of discharge after chemotherapy completion. This study compared treatment-related morbidity, mortality and cumulative hospitalization in children with AML who were discharged after chemotherapy completion (early discharge) and those who remained hospitalized. Chart abstraction data for 153 early discharge-eligible patients enrolled on a Children's Oncology Group trial were compared by discharge strategy. Targeted toxicities included viridans group streptococcal (VGS) bacteremia, hypoxia and hypotension. Early discharge occurred in 11% of courses post-Induction I. Re-admission occurred in 80-100%, but median hospital stay was 7 days shorter. Patients discharged early had higher rates of VGS (adjusted risk ratio (aRR) = 1.67, 95% CI = 1.11-2.51), hypoxia (aRR = 1.92, 95% CI = 1.06-3.48) and hypotension (aRR = 4.36, 95% CI = 2.01-9.46), but there was no difference in mortality. As pressure increases to shorten hospitalizations, these results have important implications for determining discharge practices in pediatric AML.